POSIFLEX-TECHNOLOGY
Posiflex Technology Inc., a global leader in Point of Sale (POS) systems and Online to Offline (O2O) solutions, is pleased to announce its latest flagship POS terminal series – Mozart BT. The Mozart BT Series introduces beautiful modular monitor systems that integrate high-performance computing power, the latest operating system, and user-friendly ergonomic designs. With a high degree of modularity in construction and sleek elegance in appearance, the series conceals all cables and connectors, perfectly integrating the printer, providing a sense of space economy and aesthetics that enhances Posiflex's brand identity. The small and clean footprint of the Mozart BT Series allows seamless integration into various commercial spaces such as fashion boutiques, hospitality, convenience stores, food and beverage establishments, or multifunctional storefronts. Designed for versatility, it is an ideal solution for businesses requiring an additional display on the counter board for advertising playback, offering an elegant, beautiful, and useful POS terminal solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240714496907/en/
Posiflex Mozart BT Series POS Terminals (Photo: Business Wire)
A Harmonious Work of Paper-Thin Elegance
Posiflex's Mozart BT Series, aptly named, strives to unite all its structural, functional, and aesthetic elements into a seamless harmony, reminiscent of a Symphony composition. Following the design principle of "less is more," the thinner display, host, and stand, along with narrower monitor bezels, not only reduce the system's size and weight but also enhance its functionality. Every curve and angle is meticulously crafted to convey a sense of elegance. Integrated and concealed designs ensure the elimination of exposed cables and connectors, presenting a clean and uncluttered aesthetic. The overall outcome is a sleek, harmonious, and elegant masterpiece.
Ripple Brand Identity
The ripple icon on the start button and thermal printer gives a sense of brand identity, symbolizing the continued vitality and the continuous quest for innovation and user benefit. The burgundy red on the sides of the stand suggests understated luxury and the deep, round taste associated with red wine.
Brilliant Modularity
Modular design has consistently been the pinnacle of innovation in Posiflex products, and the Mozart BT Series has elevated modularity to new heights. Each main component, from displays to the host and thermal printer, is independent, facilitating easy installation, removal for repair and maintenance, yet seamlessly integrates in function and structure when assembled into the system. The thermal printer is cleverly incorporated into the stand, becoming an integral part of the POS terminal base. Alternatively, it can function independently, showcasing a design that optimizes both space and functionality ingeniously.
User-Friendly Ergonomic Designs
The Mozart BT Series POS terminal incorporates ergonomic designs to optimize the user experience. Narrow bezels on the displays minimize interference with the user's view, directing attention to the screen. Moreover, the adjustable angles of the displays cater to the user's comfort and dynamic needs. Both main and secondary displays can be vertically oriented, aligning with current market trends. Additionally, all peripherals are positioned at the same level from the user's perspective, promoting heightened comfort.
State-of-the-Art Specifications
The Mozart BT Series POS Terminal stands out with a host of impressive features. It runs on the latest operating systems, including Android 13 with EDLA certified (GMS) or Windows 11 OS, available in both x86 and RISC variants. The terminal is powered by up to the latest 13th-generation Intel processor, ensuring top-notch performance. Users can choose between a 15" or 15.6" LCD display, notably the 15.6" main screen featuring oTP technology (typical 400 nits) for vibrant colors and high brightness. Plus, the terminal offers versatility with accessory and attachment choices, including the 3-in-1 side attachment for RFID/MSR/FPU, iButton, 2D BCR (discrete/side attached), and the detachable printer.
These features combine to provide a powerful and versatile electronic POS system with high-speed processing power and the ability to run the latest applications to meet the changing needs of the retail and hospitality industry.
About POSIFLEX Group
Posiflex Group is a global leading Commercial AIoT platform powered by smart Online-to-Offline (O2O) and Scenario-defined Embedded Appliance Solutions. Pillared by three brands, Posiflex Group consists of Posiflex as global top 5 brand in POS & Kiosk, Portwell as Embedded Foundry for AIoT Edge Compute, and KIOSK Information Systems (KIS) for managed self-service automation – together with a common mission to enable optimized productivity and superior customer journey across the connected world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240714496907/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
